SI3600276T1 - Betahistin ali njegova farmacevtsko sprejemljiva sol in inhibitor monoaminoksidaze, za uporabo pri zdravljenju ali preprečevanju enega ali več simptomov vrtoglavice pri subjektu - Google Patents
Betahistin ali njegova farmacevtsko sprejemljiva sol in inhibitor monoaminoksidaze, za uporabo pri zdravljenju ali preprečevanju enega ali več simptomov vrtoglavice pri subjektuInfo
- Publication number
- SI3600276T1 SI3600276T1 SI201830944T SI201830944T SI3600276T1 SI 3600276 T1 SI3600276 T1 SI 3600276T1 SI 201830944 T SI201830944 T SI 201830944T SI 201830944 T SI201830944 T SI 201830944T SI 3600276 T1 SI3600276 T1 SI 3600276T1
- Authority
- SI
- Slovenia
- Prior art keywords
- betahistine
- vertigo
- symptoms
- prevention
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704949.5A GB201704949D0 (en) | 2017-03-28 | 2017-03-28 | Combination treatment |
| GBGB1711677.3A GB201711677D0 (en) | 2017-07-20 | 2017-07-20 | Combination treatment |
| EP18715909.0A EP3600276B1 (en) | 2017-03-28 | 2018-03-28 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject |
| PCT/GB2018/050822 WO2018178670A1 (en) | 2017-03-28 | 2018-03-28 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3600276T1 true SI3600276T1 (sl) | 2023-08-31 |
Family
ID=61906770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201830944T SI3600276T1 (sl) | 2017-03-28 | 2018-03-28 | Betahistin ali njegova farmacevtsko sprejemljiva sol in inhibitor monoaminoksidaze, za uporabo pri zdravljenju ali preprečevanju enega ali več simptomov vrtoglavice pri subjektu |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11083718B2 (sl) |
| EP (2) | EP3600276B1 (sl) |
| DK (1) | DK3600276T3 (sl) |
| ES (1) | ES2950452T3 (sl) |
| FI (1) | FI3600276T3 (sl) |
| HR (1) | HRP20230735T1 (sl) |
| HU (1) | HUE062729T2 (sl) |
| LT (1) | LT3600276T (sl) |
| PL (1) | PL3600276T3 (sl) |
| PT (1) | PT3600276T (sl) |
| RS (1) | RS64304B1 (sl) |
| SI (1) | SI3600276T1 (sl) |
| WO (1) | WO2018178670A1 (sl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3600276T3 (da) | 2017-03-28 | 2023-07-10 | Intrabio Ltd | Betahistin, eller et farmaceutisk acceptabelt salt deraf og en monoaminoxidase-inhibitor til anvendlese til behandling eller forebyggelse af et eller flere symptomer på svimmelhed hos et individ |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| AU2009253739B2 (en) * | 2008-05-27 | 2014-02-06 | Otolanum Ag | Methods of treating mammals with eustachian tube dysfunctions |
| EP2491930A1 (en) * | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| DK3600276T3 (da) | 2017-03-28 | 2023-07-10 | Intrabio Ltd | Betahistin, eller et farmaceutisk acceptabelt salt deraf og en monoaminoxidase-inhibitor til anvendlese til behandling eller forebyggelse af et eller flere symptomer på svimmelhed hos et individ |
-
2018
- 2018-03-28 DK DK18715909.0T patent/DK3600276T3/da active
- 2018-03-28 PT PT187159090T patent/PT3600276T/pt unknown
- 2018-03-28 HR HRP20230735TT patent/HRP20230735T1/hr unknown
- 2018-03-28 WO PCT/GB2018/050822 patent/WO2018178670A1/en unknown
- 2018-03-28 LT LTEPPCT/GB2018/050822T patent/LT3600276T/lt unknown
- 2018-03-28 EP EP18715909.0A patent/EP3600276B1/en active Active
- 2018-03-28 US US16/499,087 patent/US11083718B2/en active Active
- 2018-03-28 EP EP23176227.9A patent/EP4234022A3/en active Pending
- 2018-03-28 SI SI201830944T patent/SI3600276T1/sl unknown
- 2018-03-28 PL PL18715909.0T patent/PL3600276T3/pl unknown
- 2018-03-28 ES ES18715909T patent/ES2950452T3/es active Active
- 2018-03-28 FI FIEP18715909.0T patent/FI3600276T3/fi active
- 2018-03-28 RS RS20230485A patent/RS64304B1/sr unknown
- 2018-03-28 HU HUE18715909A patent/HUE062729T2/hu unknown
-
2021
- 2021-08-06 US US17/396,064 patent/US11690830B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230285373A1 (en) | 2023-09-14 |
| EP4234022A2 (en) | 2023-08-30 |
| WO2018178670A1 (en) | 2018-10-04 |
| LT3600276T (lt) | 2023-08-10 |
| EP3600276A1 (en) | 2020-02-05 |
| EP3600276B1 (en) | 2023-05-31 |
| US11083718B2 (en) | 2021-08-10 |
| US20210361632A1 (en) | 2021-11-25 |
| US11690830B2 (en) | 2023-07-04 |
| HRP20230735T1 (hr) | 2023-10-13 |
| HUE062729T2 (hu) | 2023-12-28 |
| EP4234022A3 (en) | 2023-10-04 |
| US20210085659A1 (en) | 2021-03-25 |
| PT3600276T (pt) | 2023-07-11 |
| RS64304B1 (sr) | 2023-07-31 |
| DK3600276T3 (da) | 2023-07-10 |
| FI3600276T3 (fi) | 2023-06-29 |
| ES2950452T3 (es) | 2023-10-10 |
| PL3600276T3 (pl) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288231A (en) | An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts. | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| IL282487A (en) | TYK2 inhibitors and their use | |
| SG11202013231SA (en) | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF | |
| IL268327A (en) | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL282090A (en) | tyk2 inhibitors and uses thereof | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| IL271728A (en) | Materials, uses and treatment methods | |
| EP3431517A4 (en) | Copolymer and surface treatment | |
| HUE067036T2 (hu) | 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében | |
| NZ733451A (en) | Combination therapy for pulmonary hypertension | |
| IL273922A (en) | D-amino acid oxidase inhibitors and their therapeutic uses | |
| PL3600276T3 (pl) | Betahistyna lub jej farmaceutycznie dopuszczalna sól oraz inhibitor monoaminooksydazy do stosowania w leczeniu lub zapobieganiu jednemu lub większej liczbie objawów zawrotów głowy u osobnika | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| WO2015165980A3 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| HK1247917A1 (zh) | 與金屬和/或自由基螯合構型有關的鄰伯二胺，及其抗羰基和氧化應激的活性，及其用途 | |
| WO2016126572A3 (en) | Glucosylceramide synthase inhibitors and therapeutic methods using the same | |
| GB201519258D0 (en) | Newly identified wnt/beta-catenin signal transduction inhibitors and the use thereof in the treatment or prevention of diseases and conditions. | |
| HK1246205A1 (zh) | 在預防和/或治療皮膚損傷中使用的至少一種蛋白酶抑制劑和至少一種活性成分的組合 | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| IL290328A (en) | Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate cancer | |
| GEP20197038B (en) | Combination of at least one protease inhibitor and at least one active principle for use in the prevention and/or treatment of skin lesions | |
| ZA201600894B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes |